nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ORM1—Vemurafenib—melanoma	0.156	0.318	CbGbCtD
Fluoxetine—ALB—melanoma	0.15	0.512	CbGaD
Fluoxetine—ABCB1—melanoma	0.143	0.488	CbGaD
Fluoxetine—ALB—Vemurafenib—melanoma	0.0654	0.134	CbGbCtD
Fluoxetine—CYP1A2—Carmustine—melanoma	0.0495	0.101	CbGbCtD
Fluoxetine—CYP1A2—Vemurafenib—melanoma	0.0391	0.08	CbGbCtD
Fluoxetine—CYP3A4—Temozolomide—melanoma	0.0374	0.0765	CbGbCtD
Fluoxetine—CYP2D6—Vemurafenib—melanoma	0.0323	0.0659	CbGbCtD
Fluoxetine—CYP1A2—Dacarbazine—melanoma	0.03	0.0613	CbGbCtD
Fluoxetine—ABCB1—Dactinomycin—melanoma	0.0227	0.0465	CbGbCtD
Fluoxetine—CYP3A4—Vemurafenib—melanoma	0.0205	0.0419	CbGbCtD
Fluoxetine—CYP3A5—Docetaxel—melanoma	0.018	0.0369	CbGbCtD
Fluoxetine—ABCB1—Docetaxel—melanoma	0.0117	0.024	CbGbCtD
Fluoxetine—CYP3A4—Docetaxel—melanoma	0.00704	0.0144	CbGbCtD
Fluoxetine—Monobenzone—TYR—melanoma	0.00422	0.92	CrCbGaD
Fluoxetine—Orphenadrine—SCN10A—melanoma	0.000365	0.0796	CrCbGaD
Fluoxetine—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000203	0.00129	CcSEcCtD
Fluoxetine—Ill-defined disorder—Bleomycin—melanoma	0.000202	0.00128	CcSEcCtD
Fluoxetine—Anaemia—Bleomycin—melanoma	0.000201	0.00128	CcSEcCtD
Fluoxetine—Diarrhoea—Vemurafenib—melanoma	0.000201	0.00127	CcSEcCtD
Fluoxetine—Migraine—Docetaxel—melanoma	0.000199	0.00127	CcSEcCtD
Fluoxetine—Erythema multiforme—Temozolomide—melanoma	0.000199	0.00126	CcSEcCtD
Fluoxetine—Tinnitus—Temozolomide—melanoma	0.000197	0.00125	CcSEcCtD
Fluoxetine—Malaise—Bleomycin—melanoma	0.000196	0.00124	CcSEcCtD
Fluoxetine—Arrhythmia—Carmustine—melanoma	0.000195	0.00124	CcSEcCtD
Fluoxetine—Leukopenia—Bleomycin—melanoma	0.000195	0.00124	CcSEcCtD
Fluoxetine—Dizziness—Vemurafenib—melanoma	0.000194	0.00123	CcSEcCtD
Fluoxetine—Alopecia—Carmustine—melanoma	0.000193	0.00122	CcSEcCtD
Fluoxetine—Mental disorder—Carmustine—melanoma	0.000191	0.00121	CcSEcCtD
Fluoxetine—Ataxia—Docetaxel—melanoma	0.000191	0.00121	CcSEcCtD
Fluoxetine—Malnutrition—Carmustine—melanoma	0.00019	0.00121	CcSEcCtD
Fluoxetine—Cough—Bleomycin—melanoma	0.00019	0.0012	CcSEcCtD
Fluoxetine—Chills—Temozolomide—melanoma	0.000189	0.0012	CcSEcCtD
Fluoxetine—Dehydration—Docetaxel—melanoma	0.000188	0.0012	CcSEcCtD
Fluoxetine—Ill-defined disorder—Dactinomycin—melanoma	0.000188	0.00119	CcSEcCtD
Fluoxetine—Anaemia—Dactinomycin—melanoma	0.000188	0.00119	CcSEcCtD
Fluoxetine—Liver function test abnormal—Docetaxel—melanoma	0.000187	0.00119	CcSEcCtD
Fluoxetine—Vomiting—Vemurafenib—melanoma	0.000186	0.00118	CcSEcCtD
Fluoxetine—Alopecia—Temozolomide—melanoma	0.000186	0.00118	CcSEcCtD
Fluoxetine—Dry skin—Docetaxel—melanoma	0.000186	0.00118	CcSEcCtD
Fluoxetine—Chest pain—Bleomycin—melanoma	0.000185	0.00118	CcSEcCtD
Fluoxetine—Myalgia—Bleomycin—melanoma	0.000185	0.00118	CcSEcCtD
Fluoxetine—Orthostatic hypotension—Docetaxel—melanoma	0.000185	0.00117	CcSEcCtD
Fluoxetine—Rash—Vemurafenib—melanoma	0.000185	0.00117	CcSEcCtD
Fluoxetine—Mental disorder—Temozolomide—melanoma	0.000185	0.00117	CcSEcCtD
Fluoxetine—Dermatitis—Vemurafenib—melanoma	0.000185	0.00117	CcSEcCtD
Fluoxetine—Back pain—Carmustine—melanoma	0.000184	0.00117	CcSEcCtD
Fluoxetine—Headache—Vemurafenib—melanoma	0.000184	0.00117	CcSEcCtD
Fluoxetine—Malnutrition—Temozolomide—melanoma	0.000184	0.00116	CcSEcCtD
Fluoxetine—Breast disorder—Docetaxel—melanoma	0.000183	0.00116	CcSEcCtD
Fluoxetine—Discomfort—Bleomycin—melanoma	0.000183	0.00116	CcSEcCtD
Fluoxetine—Malaise—Dactinomycin—melanoma	0.000183	0.00116	CcSEcCtD
Fluoxetine—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000182	0.00116	CcSEcCtD
Fluoxetine—Leukopenia—Dactinomycin—melanoma	0.000182	0.00115	CcSEcCtD
Fluoxetine—Dysgeusia—Temozolomide—melanoma	0.00018	0.00114	CcSEcCtD
Fluoxetine—Confusional state—Bleomycin—melanoma	0.000179	0.00114	CcSEcCtD
Fluoxetine—Alanine aminotransferase increased—Docetaxel—melanoma	0.000179	0.00113	CcSEcCtD
Fluoxetine—Tremor—Carmustine—melanoma	0.000178	0.00113	CcSEcCtD
Fluoxetine—Anaphylactic shock—Bleomycin—melanoma	0.000178	0.00113	CcSEcCtD
Fluoxetine—Back pain—Temozolomide—melanoma	0.000178	0.00113	CcSEcCtD
Fluoxetine—Infection—Bleomycin—melanoma	0.000176	0.00112	CcSEcCtD
Fluoxetine—Anaemia—Carmustine—melanoma	0.000176	0.00111	CcSEcCtD
Fluoxetine—Dysphagia—Docetaxel—melanoma	0.000175	0.00111	CcSEcCtD
Fluoxetine—Agitation—Carmustine—melanoma	0.000175	0.00111	CcSEcCtD
Fluoxetine—Nausea—Vemurafenib—melanoma	0.000174	0.0011	CcSEcCtD
Fluoxetine—Thrombocytopenia—Bleomycin—melanoma	0.000174	0.0011	CcSEcCtD
Fluoxetine—Myalgia—Dactinomycin—melanoma	0.000173	0.0011	CcSEcCtD
Fluoxetine—Bronchospasm—Docetaxel—melanoma	0.000172	0.00109	CcSEcCtD
Fluoxetine—Tremor—Temozolomide—melanoma	0.000172	0.00109	CcSEcCtD
Fluoxetine—Discomfort—Dactinomycin—melanoma	0.000171	0.00108	CcSEcCtD
Fluoxetine—Angina pectoris—Docetaxel—melanoma	0.000171	0.00108	CcSEcCtD
Fluoxetine—Ill-defined disorder—Temozolomide—melanoma	0.00017	0.00108	CcSEcCtD
Fluoxetine—Leukopenia—Carmustine—melanoma	0.00017	0.00108	CcSEcCtD
Fluoxetine—Anaemia—Temozolomide—melanoma	0.00017	0.00108	CcSEcCtD
Fluoxetine—Anorexia—Bleomycin—melanoma	0.000169	0.00107	CcSEcCtD
Fluoxetine—Agitation—Temozolomide—melanoma	0.000169	0.00107	CcSEcCtD
Fluoxetine—Angioedema—Temozolomide—melanoma	0.000168	0.00106	CcSEcCtD
Fluoxetine—Pancytopenia—Docetaxel—melanoma	0.000166	0.00106	CcSEcCtD
Fluoxetine—Hypotension—Bleomycin—melanoma	0.000166	0.00105	CcSEcCtD
Fluoxetine—Malaise—Temozolomide—melanoma	0.000165	0.00105	CcSEcCtD
Fluoxetine—Vertigo—Temozolomide—melanoma	0.000165	0.00105	CcSEcCtD
Fluoxetine—Convulsion—Carmustine—melanoma	0.000165	0.00104	CcSEcCtD
Fluoxetine—Infection—Dactinomycin—melanoma	0.000165	0.00104	CcSEcCtD
Fluoxetine—Leukopenia—Temozolomide—melanoma	0.000164	0.00104	CcSEcCtD
Fluoxetine—Hypertension—Carmustine—melanoma	0.000164	0.00104	CcSEcCtD
Fluoxetine—Palpitations—Temozolomide—melanoma	0.000162	0.00103	CcSEcCtD
Fluoxetine—Thrombocytopenia—Dactinomycin—melanoma	0.000162	0.00103	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Bleomycin—melanoma	0.000162	0.00103	CcSEcCtD
Fluoxetine—Chest pain—Carmustine—melanoma	0.000162	0.00103	CcSEcCtD
Fluoxetine—Myalgia—Carmustine—melanoma	0.000162	0.00103	CcSEcCtD
Fluoxetine—Anxiety—Carmustine—melanoma	0.000161	0.00102	CcSEcCtD
Fluoxetine—Cough—Temozolomide—melanoma	0.00016	0.00102	CcSEcCtD
Fluoxetine—Paraesthesia—Bleomycin—melanoma	0.000159	0.00101	CcSEcCtD
Fluoxetine—Weight increased—Docetaxel—melanoma	0.000159	0.00101	CcSEcCtD
Fluoxetine—Convulsion—Temozolomide—melanoma	0.000159	0.00101	CcSEcCtD
Fluoxetine—Weight decreased—Docetaxel—melanoma	0.000158	0.00101	CcSEcCtD
Fluoxetine—Hypertension—Temozolomide—melanoma	0.000158	0.00101	CcSEcCtD
Fluoxetine—Dyspnoea—Bleomycin—melanoma	0.000158	0.001	CcSEcCtD
Fluoxetine—Anorexia—Dactinomycin—melanoma	0.000158	0.001	CcSEcCtD
Fluoxetine—Pneumonia—Docetaxel—melanoma	0.000157	0.000997	CcSEcCtD
Fluoxetine—Confusional state—Carmustine—melanoma	0.000156	0.000992	CcSEcCtD
Fluoxetine—Myalgia—Temozolomide—melanoma	0.000156	0.000991	CcSEcCtD
Fluoxetine—Arthralgia—Temozolomide—melanoma	0.000156	0.000991	CcSEcCtD
Fluoxetine—Anxiety—Temozolomide—melanoma	0.000156	0.000988	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000155	0.000985	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000155	0.000983	CcSEcCtD
Fluoxetine—Discomfort—Temozolomide—melanoma	0.000154	0.00098	CcSEcCtD
Fluoxetine—Decreased appetite—Bleomycin—melanoma	0.000154	0.000979	CcSEcCtD
Fluoxetine—Infection—Carmustine—melanoma	0.000154	0.000977	CcSEcCtD
Fluoxetine—Acute coronary syndrome—Docetaxel—melanoma	0.000154	0.000977	CcSEcCtD
Fluoxetine—Renal failure—Docetaxel—melanoma	0.000154	0.000974	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Docetaxel—melanoma	0.000153	0.000971	CcSEcCtD
Fluoxetine—Myocardial infarction—Docetaxel—melanoma	0.000153	0.000971	CcSEcCtD
Fluoxetine—Dry mouth—Temozolomide—melanoma	0.000153	0.00097	CcSEcCtD
Fluoxetine—Stomatitis—Docetaxel—melanoma	0.000152	0.000966	CcSEcCtD
Fluoxetine—Jaundice—Docetaxel—melanoma	0.000152	0.000966	CcSEcCtD
Fluoxetine—Pain—Bleomycin—melanoma	0.000152	0.000964	CcSEcCtD
Fluoxetine—Conjunctivitis—Docetaxel—melanoma	0.000152	0.000963	CcSEcCtD
Fluoxetine—Thrombocytopenia—Carmustine—melanoma	0.000152	0.000963	CcSEcCtD
Fluoxetine—Tachycardia—Carmustine—melanoma	0.000151	0.00096	CcSEcCtD
Fluoxetine—Confusional state—Temozolomide—melanoma	0.000151	0.000958	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000151	0.000957	CcSEcCtD
Fluoxetine—Anaphylactic shock—Temozolomide—melanoma	0.00015	0.00095	CcSEcCtD
Fluoxetine—Infection—Temozolomide—melanoma	0.000149	0.000944	CcSEcCtD
Fluoxetine—Anorexia—Carmustine—melanoma	0.000148	0.000937	CcSEcCtD
Fluoxetine—Epistaxis—Docetaxel—melanoma	0.000147	0.000935	CcSEcCtD
Fluoxetine—Thrombocytopenia—Temozolomide—melanoma	0.000147	0.000931	CcSEcCtD
Fluoxetine—Feeling abnormal—Bleomycin—melanoma	0.000146	0.000928	CcSEcCtD
Fluoxetine—Skin disorder—Temozolomide—melanoma	0.000145	0.000923	CcSEcCtD
Fluoxetine—Hypotension—Carmustine—melanoma	0.000145	0.000919	CcSEcCtD
Fluoxetine—Hyperhidrosis—Temozolomide—melanoma	0.000145	0.000919	CcSEcCtD
Fluoxetine—Decreased appetite—Dactinomycin—melanoma	0.000144	0.000913	CcSEcCtD
Fluoxetine—Fatigue—Dactinomycin—melanoma	0.000143	0.000906	CcSEcCtD
Fluoxetine—Anorexia—Temozolomide—melanoma	0.000143	0.000906	CcSEcCtD
Fluoxetine—Pain—Dactinomycin—melanoma	0.000142	0.000899	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Carmustine—melanoma	0.000141	0.000896	CcSEcCtD
Fluoxetine—Urticaria—Bleomycin—melanoma	0.000141	0.000895	CcSEcCtD
Fluoxetine—Haemoglobin—Docetaxel—melanoma	0.000141	0.000894	CcSEcCtD
Fluoxetine—Rhinitis—Docetaxel—melanoma	0.000141	0.000892	CcSEcCtD
Fluoxetine—Body temperature increased—Bleomycin—melanoma	0.00014	0.000891	CcSEcCtD
Fluoxetine—Haemorrhage—Docetaxel—melanoma	0.00014	0.00089	CcSEcCtD
Fluoxetine—Hepatitis—Docetaxel—melanoma	0.00014	0.00089	CcSEcCtD
Fluoxetine—Insomnia—Carmustine—melanoma	0.00014	0.00089	CcSEcCtD
Fluoxetine—Hypoaesthesia—Docetaxel—melanoma	0.000139	0.000885	CcSEcCtD
Fluoxetine—Paraesthesia—Carmustine—melanoma	0.000139	0.000883	CcSEcCtD
Fluoxetine—Pharyngitis—Docetaxel—melanoma	0.000139	0.000883	CcSEcCtD
Fluoxetine—Dyspnoea—Carmustine—melanoma	0.000138	0.000877	CcSEcCtD
Fluoxetine—Oedema peripheral—Docetaxel—melanoma	0.000138	0.000876	CcSEcCtD
Fluoxetine—Somnolence—Carmustine—melanoma	0.000138	0.000874	CcSEcCtD
Fluoxetine—Feeling abnormal—Dactinomycin—melanoma	0.000136	0.000866	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Temozolomide—melanoma	0.000136	0.000866	CcSEcCtD
Fluoxetine—Insomnia—Temozolomide—melanoma	0.000135	0.00086	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Dactinomycin—melanoma	0.000135	0.000859	CcSEcCtD
Fluoxetine—Visual impairment—Docetaxel—melanoma	0.000135	0.000857	CcSEcCtD
Fluoxetine—Decreased appetite—Carmustine—melanoma	0.000135	0.000855	CcSEcCtD
Fluoxetine—Paraesthesia—Temozolomide—melanoma	0.000134	0.000853	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Carmustine—melanoma	0.000134	0.000849	CcSEcCtD
Fluoxetine—Dyspnoea—Temozolomide—melanoma	0.000134	0.000847	CcSEcCtD
Fluoxetine—Somnolence—Temozolomide—melanoma	0.000133	0.000845	CcSEcCtD
Fluoxetine—Erythema multiforme—Docetaxel—melanoma	0.000133	0.000841	CcSEcCtD
Fluoxetine—Constipation—Carmustine—melanoma	0.000133	0.000841	CcSEcCtD
Fluoxetine—Pain—Carmustine—melanoma	0.000133	0.000841	CcSEcCtD
Fluoxetine—Dyspepsia—Temozolomide—melanoma	0.000132	0.000837	CcSEcCtD
Fluoxetine—Body temperature increased—Dactinomycin—melanoma	0.000131	0.000831	CcSEcCtD
Fluoxetine—Abdominal pain—Dactinomycin—melanoma	0.000131	0.000831	CcSEcCtD
Fluoxetine—Hypersensitivity—Bleomycin—melanoma	0.000131	0.00083	CcSEcCtD
Fluoxetine—Decreased appetite—Temozolomide—melanoma	0.00013	0.000826	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Temozolomide—melanoma	0.000129	0.000821	CcSEcCtD
Fluoxetine—Fatigue—Temozolomide—melanoma	0.000129	0.000819	CcSEcCtD
Fluoxetine—Constipation—Temozolomide—melanoma	0.000128	0.000813	CcSEcCtD
Fluoxetine—Pain—Temozolomide—melanoma	0.000128	0.000813	CcSEcCtD
Fluoxetine—Feeling abnormal—Carmustine—melanoma	0.000128	0.00081	CcSEcCtD
Fluoxetine—Asthenia—Bleomycin—melanoma	0.000127	0.000808	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Carmustine—melanoma	0.000127	0.000804	CcSEcCtD
Fluoxetine—Chills—Docetaxel—melanoma	0.000126	0.000798	CcSEcCtD
Fluoxetine—Pruritus—Bleomycin—melanoma	0.000126	0.000797	CcSEcCtD
Fluoxetine—Arrhythmia—Docetaxel—melanoma	0.000125	0.000795	CcSEcCtD
Fluoxetine—Alopecia—Docetaxel—melanoma	0.000124	0.000786	CcSEcCtD
Fluoxetine—Feeling abnormal—Temozolomide—melanoma	0.000123	0.000783	CcSEcCtD
Fluoxetine—Mental disorder—Docetaxel—melanoma	0.000123	0.000779	CcSEcCtD
Fluoxetine—Abdominal pain—Carmustine—melanoma	0.000123	0.000777	CcSEcCtD
Fluoxetine—Body temperature increased—Carmustine—melanoma	0.000123	0.000777	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Temozolomide—melanoma	0.000122	0.000777	CcSEcCtD
Fluoxetine—Malnutrition—Docetaxel—melanoma	0.000122	0.000774	CcSEcCtD
Fluoxetine—Hypersensitivity—Dactinomycin—melanoma	0.000122	0.000774	CcSEcCtD
Fluoxetine—Dysgeusia—Docetaxel—melanoma	0.00012	0.000758	CcSEcCtD
Fluoxetine—Urticaria—Temozolomide—melanoma	0.000119	0.000755	CcSEcCtD
Fluoxetine—Asthenia—Dactinomycin—melanoma	0.000119	0.000754	CcSEcCtD
Fluoxetine—Abdominal pain—Temozolomide—melanoma	0.000118	0.000751	CcSEcCtD
Fluoxetine—Body temperature increased—Temozolomide—melanoma	0.000118	0.000751	CcSEcCtD
Fluoxetine—Back pain—Docetaxel—melanoma	0.000118	0.000749	CcSEcCtD
Fluoxetine—Muscle spasms—Docetaxel—melanoma	0.000117	0.000745	CcSEcCtD
Fluoxetine—Hypersensitivity—Carmustine—melanoma	0.000114	0.000725	CcSEcCtD
Fluoxetine—Diarrhoea—Dactinomycin—melanoma	0.000113	0.000719	CcSEcCtD
Fluoxetine—Vomiting—Bleomycin—melanoma	0.000113	0.000716	CcSEcCtD
Fluoxetine—Anaemia—Docetaxel—melanoma	0.000113	0.000716	CcSEcCtD
Fluoxetine—Rash—Bleomycin—melanoma	0.000112	0.00071	CcSEcCtD
Fluoxetine—Dermatitis—Bleomycin—melanoma	0.000112	0.00071	CcSEcCtD
Fluoxetine—Asthenia—Carmustine—melanoma	0.000111	0.000706	CcSEcCtD
Fluoxetine—Hypersensitivity—Temozolomide—melanoma	0.00011	0.0007	CcSEcCtD
Fluoxetine—Syncope—Docetaxel—melanoma	0.000109	0.000695	CcSEcCtD
Fluoxetine—Leukopenia—Docetaxel—melanoma	0.000109	0.000693	CcSEcCtD
Fluoxetine—Palpitations—Docetaxel—melanoma	0.000108	0.000684	CcSEcCtD
Fluoxetine—Asthenia—Temozolomide—melanoma	0.000107	0.000682	CcSEcCtD
Fluoxetine—Loss of consciousness—Docetaxel—melanoma	0.000107	0.000681	CcSEcCtD
Fluoxetine—Cough—Docetaxel—melanoma	0.000106	0.000676	CcSEcCtD
Fluoxetine—Diarrhoea—Carmustine—melanoma	0.000106	0.000673	CcSEcCtD
Fluoxetine—Pruritus—Temozolomide—melanoma	0.000106	0.000672	CcSEcCtD
Fluoxetine—Convulsion—Docetaxel—melanoma	0.000106	0.000671	CcSEcCtD
Fluoxetine—Nausea—Bleomycin—melanoma	0.000105	0.000669	CcSEcCtD
Fluoxetine—Hypertension—Docetaxel—melanoma	0.000105	0.000669	CcSEcCtD
Fluoxetine—Vomiting—Dactinomycin—melanoma	0.000105	0.000668	CcSEcCtD
Fluoxetine—Rash—Dactinomycin—melanoma	0.000104	0.000663	CcSEcCtD
Fluoxetine—Arthralgia—Docetaxel—melanoma	0.000104	0.000659	CcSEcCtD
Fluoxetine—Chest pain—Docetaxel—melanoma	0.000104	0.000659	CcSEcCtD
Fluoxetine—Myalgia—Docetaxel—melanoma	0.000104	0.000659	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000103	0.000655	CcSEcCtD
Fluoxetine—Dizziness—Carmustine—melanoma	0.000102	0.00065	CcSEcCtD
Fluoxetine—Diarrhoea—Temozolomide—melanoma	0.000102	0.00065	CcSEcCtD
Fluoxetine—Dry mouth—Docetaxel—melanoma	0.000102	0.000645	CcSEcCtD
Fluoxetine—Confusional state—Docetaxel—melanoma	0.0001	0.000637	CcSEcCtD
Fluoxetine—Anaphylactic shock—Docetaxel—melanoma	9.96e-05	0.000632	CcSEcCtD
Fluoxetine—Dizziness—Temozolomide—melanoma	9.9e-05	0.000629	CcSEcCtD
Fluoxetine—Infection—Docetaxel—melanoma	9.9e-05	0.000628	CcSEcCtD
Fluoxetine—Vomiting—Carmustine—melanoma	9.85e-05	0.000625	CcSEcCtD
Fluoxetine—Nausea—Dactinomycin—melanoma	9.84e-05	0.000624	CcSEcCtD
Fluoxetine—Shock—Docetaxel—melanoma	9.8e-05	0.000622	CcSEcCtD
Fluoxetine—Rash—Carmustine—melanoma	9.77e-05	0.00062	CcSEcCtD
Fluoxetine—Dermatitis—Carmustine—melanoma	9.76e-05	0.00062	CcSEcCtD
Fluoxetine—Thrombocytopenia—Docetaxel—melanoma	9.75e-05	0.000619	CcSEcCtD
Fluoxetine—Tachycardia—Docetaxel—melanoma	9.72e-05	0.000617	CcSEcCtD
Fluoxetine—Headache—Carmustine—melanoma	9.71e-05	0.000616	CcSEcCtD
Fluoxetine—Skin disorder—Docetaxel—melanoma	9.67e-05	0.000614	CcSEcCtD
Fluoxetine—Vomiting—Temozolomide—melanoma	9.52e-05	0.000604	CcSEcCtD
Fluoxetine—Anorexia—Docetaxel—melanoma	9.49e-05	0.000602	CcSEcCtD
Fluoxetine—Rash—Temozolomide—melanoma	9.44e-05	0.000599	CcSEcCtD
Fluoxetine—Dermatitis—Temozolomide—melanoma	9.44e-05	0.000599	CcSEcCtD
Fluoxetine—Headache—Temozolomide—melanoma	9.38e-05	0.000595	CcSEcCtD
Fluoxetine—Hypotension—Docetaxel—melanoma	9.31e-05	0.000591	CcSEcCtD
Fluoxetine—Nausea—Carmustine—melanoma	9.21e-05	0.000584	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Docetaxel—melanoma	9.07e-05	0.000576	CcSEcCtD
Fluoxetine—Insomnia—Docetaxel—melanoma	9.01e-05	0.000572	CcSEcCtD
Fluoxetine—Paraesthesia—Docetaxel—melanoma	8.94e-05	0.000568	CcSEcCtD
Fluoxetine—Nausea—Temozolomide—melanoma	8.9e-05	0.000565	CcSEcCtD
Fluoxetine—Dyspnoea—Docetaxel—melanoma	8.88e-05	0.000564	CcSEcCtD
Fluoxetine—Somnolence—Docetaxel—melanoma	8.85e-05	0.000562	CcSEcCtD
Fluoxetine—Dyspepsia—Docetaxel—melanoma	8.77e-05	0.000556	CcSEcCtD
Fluoxetine—Decreased appetite—Docetaxel—melanoma	8.66e-05	0.000549	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Docetaxel—melanoma	8.6e-05	0.000546	CcSEcCtD
Fluoxetine—Fatigue—Docetaxel—melanoma	8.59e-05	0.000545	CcSEcCtD
Fluoxetine—Pain—Docetaxel—melanoma	8.52e-05	0.000541	CcSEcCtD
Fluoxetine—Constipation—Docetaxel—melanoma	8.52e-05	0.000541	CcSEcCtD
Fluoxetine—Feeling abnormal—Docetaxel—melanoma	8.21e-05	0.000521	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Docetaxel—melanoma	8.14e-05	0.000517	CcSEcCtD
Fluoxetine—Body temperature increased—Docetaxel—melanoma	7.87e-05	0.0005	CcSEcCtD
Fluoxetine—Abdominal pain—Docetaxel—melanoma	7.87e-05	0.0005	CcSEcCtD
Fluoxetine—Hypersensitivity—Docetaxel—melanoma	7.34e-05	0.000466	CcSEcCtD
Fluoxetine—Asthenia—Docetaxel—melanoma	7.15e-05	0.000453	CcSEcCtD
Fluoxetine—Pruritus—Docetaxel—melanoma	7.05e-05	0.000447	CcSEcCtD
Fluoxetine—Diarrhoea—Docetaxel—melanoma	6.82e-05	0.000432	CcSEcCtD
Fluoxetine—Dizziness—Docetaxel—melanoma	6.59e-05	0.000418	CcSEcCtD
Fluoxetine—Vomiting—Docetaxel—melanoma	6.33e-05	0.000402	CcSEcCtD
Fluoxetine—Rash—Docetaxel—melanoma	6.28e-05	0.000399	CcSEcCtD
Fluoxetine—Dermatitis—Docetaxel—melanoma	6.27e-05	0.000398	CcSEcCtD
Fluoxetine—Headache—Docetaxel—melanoma	6.24e-05	0.000396	CcSEcCtD
Fluoxetine—Nausea—Docetaxel—melanoma	5.92e-05	0.000375	CcSEcCtD
Fluoxetine—HTR2A—Signaling Pathways—SPP1—melanoma	5.44e-06	9.84e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—NRAS—melanoma	5.44e-06	9.83e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KDR—melanoma	5.43e-06	9.82e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAP2K2—melanoma	5.42e-06	9.81e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CXCL8—melanoma	5.42e-06	9.79e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GNAQ—melanoma	5.41e-06	9.79e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CD44—melanoma	5.41e-06	9.79e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GNAQ—melanoma	5.37e-06	9.7e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CD44—melanoma	5.37e-06	9.7e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PLA2G6—melanoma	5.32e-06	9.62e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	5.26e-06	9.5e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—FN1—melanoma	5.23e-06	9.45e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP17A1—melanoma	5.22e-06	9.44e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	5.21e-06	9.41e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MAPK3—melanoma	5.21e-06	9.41e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP1B1—melanoma	5.19e-06	9.38e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL2—melanoma	5.18e-06	9.36e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ABCB1—melanoma	5.18e-06	9.36e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TERT—melanoma	5.16e-06	9.33e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	5.15e-06	9.32e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP1B1—melanoma	5.15e-06	9.3e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RAC1—melanoma	5.14e-06	9.3e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOTCH1—melanoma	5.12e-06	9.25e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	5.09e-06	9.2e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CD80—melanoma	5.01e-06	9.06e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CG—melanoma	5.01e-06	9.05e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KIT—melanoma	5.01e-06	9.05e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APC—melanoma	5.01e-06	9.05e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—NRAS—melanoma	5.01e-06	9.05e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	4.98e-06	9e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MAPK1—melanoma	4.96e-06	8.96e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGF—melanoma	4.95e-06	8.94e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GNA11—melanoma	4.93e-06	8.92e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HIF1A—melanoma	4.93e-06	8.92e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—FASN—melanoma	4.83e-06	8.73e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK3—melanoma	4.79e-06	8.67e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—VCAN—melanoma	4.78e-06	8.64e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PRKCA—melanoma	4.76e-06	8.61e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—SLC5A5—melanoma	4.75e-06	8.59e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ERCC2—melanoma	4.73e-06	8.54e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KDR—melanoma	4.72e-06	8.53e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—BRAF—melanoma	4.7e-06	8.5e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—KRAS—melanoma	4.68e-06	8.46e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ABCB1—melanoma	4.65e-06	8.4e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GNAQ—melanoma	4.59e-06	8.29e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CD44—melanoma	4.59e-06	8.29e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IGF1—melanoma	4.58e-06	8.28e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK1—melanoma	4.56e-06	8.24e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—EGFR—melanoma	4.56e-06	8.24e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	4.54e-06	8.21e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FN1—melanoma	4.54e-06	8.21e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	4.49e-06	8.12e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	4.45e-06	8.05e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOTCH1—melanoma	4.44e-06	8.03e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CG—melanoma	4.43e-06	8.01e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAP2K1—melanoma	4.43e-06	8.01e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CD—melanoma	4.4e-06	7.95e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP1B1—melanoma	4.4e-06	7.95e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CA—melanoma	4.36e-06	7.88e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CD80—melanoma	4.35e-06	7.87e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APC—melanoma	4.35e-06	7.86e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CG—melanoma	4.35e-06	7.86e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KIT—melanoma	4.35e-06	7.86e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—NRAS—melanoma	4.35e-06	7.86e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CG—melanoma	4.33e-06	7.83e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—KRAS—melanoma	4.31e-06	7.79e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CA—melanoma	4.3e-06	7.77e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGF—melanoma	4.3e-06	7.77e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PPARG—melanoma	4.28e-06	7.74e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PRKCA—melanoma	4.28e-06	7.73e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ABCB1—melanoma	4.27e-06	7.73e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ERCC2—melanoma	4.24e-06	7.67e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ABCB1—melanoma	4.24e-06	7.66e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—FGF2—melanoma	4.21e-06	7.62e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PPARG—melanoma	4.18e-06	7.56e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PRKCA—melanoma	4.17e-06	7.55e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK3—melanoma	4.16e-06	7.52e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—melanoma	4.16e-06	7.52e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ERCC2—melanoma	4.14e-06	7.48e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—BRAF—melanoma	4.09e-06	7.39e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP17A1—melanoma	4.03e-06	7.29e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IGF1—melanoma	3.98e-06	7.19e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—HRAS—melanoma	3.98e-06	7.19e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK1—melanoma	3.96e-06	7.16e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EGFR—melanoma	3.96e-06	7.16e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CA—melanoma	3.96e-06	7.15e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MDM2—melanoma	3.94e-06	7.13e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PRKCA—melanoma	3.93e-06	7.11e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.91e-06	7.08e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ERCC2—melanoma	3.9e-06	7.05e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PRKCA—melanoma	3.9e-06	7.05e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CD—melanoma	3.9e-06	7.05e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ERBB2—melanoma	3.89e-06	7.03e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.88e-06	7.02e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ERCC2—melanoma	3.87e-06	6.99e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ALB—melanoma	3.85e-06	6.96e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAP2K1—melanoma	3.85e-06	6.95e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CB—melanoma	3.84e-06	6.93e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CD—melanoma	3.82e-06	6.91e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CD—melanoma	3.81e-06	6.89e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GNA11—melanoma	3.81e-06	6.88e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CA—melanoma	3.78e-06	6.84e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ALB—melanoma	3.76e-06	6.8e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—KRAS—melanoma	3.74e-06	6.76e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CG—melanoma	3.73e-06	6.75e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—FASN—melanoma	3.73e-06	6.74e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCL8—melanoma	3.69e-06	6.66e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SLC5A5—melanoma	3.67e-06	6.63e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HRAS—melanoma	3.66e-06	6.62e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FGF2—melanoma	3.66e-06	6.61e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ABCB1—melanoma	3.62e-06	6.55e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PPARG—melanoma	3.6e-06	6.51e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1B—melanoma	3.6e-06	6.51e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—AKT1—melanoma	3.56e-06	6.44e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CD44—melanoma	3.54e-06	6.4e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GNAQ—melanoma	3.54e-06	6.4e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CASP3—melanoma	3.53e-06	6.38e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL2—melanoma	3.52e-06	6.37e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.51e-06	6.35e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—AKT1—melanoma	3.51e-06	6.35e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6—melanoma	3.5e-06	6.34e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CA—melanoma	3.44e-06	6.21e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCND1—melanoma	3.43e-06	6.21e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MDM2—melanoma	3.42e-06	6.19e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CTNNB1—melanoma	3.4e-06	6.15e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CB—melanoma	3.4e-06	6.14e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP1B1—melanoma	3.39e-06	6.14e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ERBB2—melanoma	3.37e-06	6.1e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTGS2—melanoma	3.37e-06	6.09e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CG—melanoma	3.35e-06	6.06e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—melanoma	3.33e-06	6.03e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PRKCA—melanoma	3.33e-06	6.02e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CB—melanoma	3.33e-06	6.02e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1A—melanoma	3.32e-06	6e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CB—melanoma	3.32e-06	6e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTEN—melanoma	3.31e-06	5.99e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ERCC2—melanoma	3.31e-06	5.98e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NFKB1—melanoma	3.3e-06	5.96e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS2—melanoma	3.29e-06	5.95e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CD—melanoma	3.28e-06	5.93e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CG—melanoma	3.27e-06	5.91e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PPARG—melanoma	3.23e-06	5.85e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—AKT1—melanoma	3.23e-06	5.84e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.2e-06	5.79e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCL8—melanoma	3.2e-06	5.79e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HRAS—melanoma	3.18e-06	5.75e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PPARG—melanoma	3.16e-06	5.71e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1B—melanoma	3.13e-06	5.65e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—AKT1—melanoma	3.09e-06	5.59e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CG—melanoma	3.08e-06	5.57e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CASP3—melanoma	3.06e-06	5.54e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL2—melanoma	3.06e-06	5.53e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CG—melanoma	3.05e-06	5.52e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6—melanoma	3.04e-06	5.5e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—melanoma	2.99e-06	5.41e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCND1—melanoma	2.98e-06	5.39e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PPARG—melanoma	2.97e-06	5.38e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—melanoma	2.96e-06	5.36e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NRAS—melanoma	2.96e-06	5.34e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CTNNB1—melanoma	2.95e-06	5.34e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PPARG—melanoma	2.95e-06	5.33e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CD—melanoma	2.95e-06	5.32e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTEN—melanoma	2.94e-06	5.31e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ALB—melanoma	2.91e-06	5.26e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—melanoma	2.89e-06	5.23e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1A—melanoma	2.88e-06	5.21e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTEN—melanoma	2.88e-06	5.2e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CD—melanoma	2.87e-06	5.2e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTEN—melanoma	2.87e-06	5.19e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NFKB1—melanoma	2.86e-06	5.18e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CB—melanoma	2.86e-06	5.17e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ALB—melanoma	2.84e-06	5.13e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS2—melanoma	2.83e-06	5.12e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK3—melanoma	2.83e-06	5.12e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—AKT1—melanoma	2.81e-06	5.08e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ABCB1—melanoma	2.79e-06	5.05e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—melanoma	2.75e-06	4.98e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.74e-06	4.95e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CD—melanoma	2.71e-06	4.9e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK1—melanoma	2.69e-06	4.87e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGFR—melanoma	2.69e-06	4.87e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CD—melanoma	2.69e-06	4.85e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ALB—melanoma	2.67e-06	4.83e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ALB—melanoma	2.65e-06	4.79e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CG—melanoma	2.61e-06	4.72e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—melanoma	2.6e-06	4.7e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—melanoma	2.57e-06	4.65e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PRKCA—melanoma	2.57e-06	4.65e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NRAS—melanoma	2.57e-06	4.64e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CB—melanoma	2.57e-06	4.64e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ERCC2—melanoma	2.55e-06	4.61e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KRAS—melanoma	2.54e-06	4.6e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS2—melanoma	2.54e-06	4.6e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PPARG—melanoma	2.52e-06	4.55e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CB—melanoma	2.51e-06	4.53e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS2—melanoma	2.48e-06	4.49e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTEN—melanoma	2.47e-06	4.47e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK3—melanoma	2.46e-06	4.45e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—melanoma	2.39e-06	4.32e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CB—melanoma	2.36e-06	4.27e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CB—melanoma	2.34e-06	4.23e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK1—melanoma	2.34e-06	4.23e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS2—melanoma	2.34e-06	4.23e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGFR—melanoma	2.34e-06	4.23e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CA—melanoma	2.34e-06	4.23e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS2—melanoma	2.32e-06	4.19e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CD—melanoma	2.29e-06	4.15e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALB—melanoma	2.27e-06	4.1e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—melanoma	2.26e-06	4.09e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTEN—melanoma	2.22e-06	4.01e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KRAS—melanoma	2.21e-06	3.99e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTEN—melanoma	2.17e-06	3.91e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HRAS—melanoma	2.16e-06	3.91e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CA—melanoma	2.07e-06	3.74e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6—melanoma	2.07e-06	3.74e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTEN—melanoma	2.04e-06	3.69e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CA—melanoma	2.03e-06	3.67e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CA—melanoma	2.02e-06	3.66e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTEN—melanoma	2.02e-06	3.66e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CG—melanoma	2.01e-06	3.64e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CB—melanoma	2e-06	3.62e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS2—melanoma	1.98e-06	3.58e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—melanoma	1.96e-06	3.55e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPARG—melanoma	1.94e-06	3.52e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—AKT1—melanoma	1.91e-06	3.45e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HRAS—melanoma	1.88e-06	3.4e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6—melanoma	1.8e-06	3.25e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CD—melanoma	1.77e-06	3.2e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALB—melanoma	1.75e-06	3.16e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CA—melanoma	1.74e-06	3.15e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTEN—melanoma	1.73e-06	3.12e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AKT1—melanoma	1.69e-06	3.06e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKT1—melanoma	1.66e-06	3e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AKT1—melanoma	1.65e-06	2.99e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CA—melanoma	1.57e-06	2.83e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CB—melanoma	1.54e-06	2.79e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS2—melanoma	1.53e-06	2.77e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CA—melanoma	1.53e-06	2.76e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CA—melanoma	1.44e-06	2.6e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CA—melanoma	1.43e-06	2.58e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AKT1—melanoma	1.42e-06	2.57e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTEN—melanoma	1.33e-06	2.41e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AKT1—melanoma	1.28e-06	2.31e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AKT1—melanoma	1.25e-06	2.26e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CA—melanoma	1.22e-06	2.2e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AKT1—melanoma	1.18e-06	2.13e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AKT1—melanoma	1.17e-06	2.11e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AKT1—melanoma	9.96e-07	1.8e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CA—melanoma	9.41e-07	1.7e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AKT1—melanoma	7.69e-07	1.39e-05	CbGpPWpGaD
